secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVANOS MEDICAL, INC. (AVNS)
CIK:        0001606498
Form:       8-K/A
Filed at:   2025-04-18T23:59:59+00:00
Accession:  0001606498-25-000063
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avanos appoints David Pacitti as CEO, effective April 14, 2025; compensation disclosed
--------------------------------------------------------------------------------

- David Pacitti, former Siemens Healthineers Americas President, becomes CEO effective April 14, 2025.
- Compensation: $1.05M base salary, 110% bonus target, $5M annual LTI target for 2026.
- One-time equity awards: $3.5M PRSUs (stock price hurdles $20-$33) and $3.5M TRSUs (3-year vest).
- Receives $500K cash sign-on; also serves on Orchestra BioMed (OBIO) board since March 2024.
- Interim CEO Michael Greiner to continue until Pacitti starts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1606498/000160649825000063/0001606498-25-000063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1606498/000160649825000063/avns-20250314.htm
  HTML page:      https://secwatch.observer/filing/0001606498-25-000063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer